Home Barinthus Biotherapeutics

Barinthus Biotherapeutics

In operation
IPO
Developer of Novel T Cell Immunotherapy

Basic Information

Barinthus Biotherapeutics plc (formerly Vaccitech plc) is a clinical-stage biopharmaceutical company focused on developing novel T-cell immunotherapies to harness the immune system to combat chronic infectious diseases, autoimmune disorders, and cancer.
Barinthus Biotherapeutics plc
Oxford,England,United Kingdom
more than 500 people
January 01, 2016
pippa@vaccitech.co.uk